Companies
/Healthcare
Compugen Ltd
$2.34
▼ $0.15 (−6.02%) today
Markets closed · 12:28am ET
Fundamentals
Market Cap
$235.9M
P/E Ratio
6.6
Profit Margin
47.6%
Revenue (TTM)
$74.0M
EPS (TTM)
$0.38
52-Week Range
$1 – $3
Street Target
$4.60
About Compugen
Compugen Ltd is a pioneer in the field of therapeutic discovery and development, focusing on immuno-oncology treatments. With a robust pipeline that includes treatments for solid tumors, advanced malignancies, and specific cancers like non-small cell lung cancer and head and neck squamous cell carcinoma, Compugen is at the forefront of developing innovative antibodies. The company collaborates with industry giants such as Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca, and engages in cutting-edge research with Johns Hopkins School of Medicine. Founded in 1993 and based in Holon, Israel, Compugen is dedicated to advancing cancer treatment through groundbreaking research.